693 related articles for article (PubMed ID: 15163332)
1. Extraocular muscle antibodies and the occurrence of ophthalmopathy in Graves' disease.
de Bellis A; Perrino S; Coronella C; Sansone D; Ruocco G; Tirelli G; Di Martino S; Conte M; Bellastella G; Wall JR; Bellastella A; Bizzarro A
Clin Endocrinol (Oxf); 2004 Jun; 60(6):694-8. PubMed ID: 15163332
[TBL] [Abstract][Full Text] [Related]
2. Relationship between longitudinal behaviour of some markers of eye autoimmunity and changes in ocular findings in patients with Graves' ophthalmopathy receiving corticosteroid therapy.
De Bellis A; Bizzarro A; Conte M; Coronella C; Solimeno S; Perrino S; Sansone D; Guaglione M; Wall JR; Bellastella A
Clin Endocrinol (Oxf); 2003 Sep; 59(3):388-95. PubMed ID: 12919164
[TBL] [Abstract][Full Text] [Related]
3. Serum antibodies to collagen XIII: a further good marker of active Graves' ophthalmopathy.
De Bellis A; Sansone D; Coronella C; Conte M; Iorio S; Perrino S; Battaglia M; Bellastella G; Wall JR; Bellastella A; Bizzarro A
Clin Endocrinol (Oxf); 2005 Jan; 62(1):24-9. PubMed ID: 15638866
[TBL] [Abstract][Full Text] [Related]
4. Antibodies targeting the calcium binding skeletal muscle protein calsequestrin are specific markers of ophthalmopathy and sensitive indicators of ocular myopathy in patients with Graves' disease.
Gopinath B; Musselman R; Beard N; El-Kaissi S; Tani J; Adams CL; Wall JR
Clin Exp Immunol; 2006 Jul; 145(1):56-62. PubMed ID: 16792674
[TBL] [Abstract][Full Text] [Related]
5. The relationship between anti-human eye muscle antibodies and thyroid function, anti-TSH receptor antibodies and eye symptoms in Graves' ophthalmopathy.
Molnár I; Balázs C
Wien Klin Wochenschr; 1992; 104(24):744-7. PubMed ID: 1363165
[TBL] [Abstract][Full Text] [Related]
6. [The role of antibodies in Graves' ophthalmopathy].
Molnár I; Balázs C
Orv Hetil; 1991 Sep; 132(38):2097-100. PubMed ID: 1923482
[TBL] [Abstract][Full Text] [Related]
7. Comparative study on IgG and IgA antibodies against human thyroid and eye-muscle antigens in Graves' ophthalmopathy.
Molnár I; Balázs C
Acta Med Hung; 1991; 48(1-2):13-21. PubMed ID: 1813853
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of Grave's ophthalmopathy with high doses of corticosteroids].
Cirić J; Zarković M; Stojanović M; Pepenezić Z; Randjelović G; Gligorović M; Trbojević B; Drezgić M; Nesović M
Srp Arh Celok Lek; 2000; 128(5-6):179-83. PubMed ID: 11089418
[TBL] [Abstract][Full Text] [Related]
9. Serum antibodies against the flavoprotein subunit of succinate dehydrogenase are sensitive markers of eye muscle autoimmunity in patients with Graves' hyperthyroidism.
Gunji K; De Bellis A; Kubota S; Swanson J; Wengrowicz S; Cochran B; Ackrell BA; Salvi M; Bellastella A; Bizzarro A; Sinisi AA; Wall JR
J Clin Endocrinol Metab; 1999 Apr; 84(4):1255-62. PubMed ID: 10199764
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical staining of normal and Graves' extraocular muscle.
Tallstedt L; Norberg R
Invest Ophthalmol Vis Sci; 1988 Feb; 29(2):175-84. PubMed ID: 2448263
[TBL] [Abstract][Full Text] [Related]
11. Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies.
Eckstein AK; Plicht M; Lax H; Hirche H; Quadbeck B; Mann K; Steuhl KP; Esser J; Morgenthaler NG
Clin Endocrinol (Oxf); 2004 Nov; 61(5):612-8. PubMed ID: 15521965
[TBL] [Abstract][Full Text] [Related]
12. Soluble interleukin-2 receptor in sera of patients with Graves' disease.
Balázs C; Farid NR
Acta Med Hung; 1991; 48(1-2):3-11. PubMed ID: 1813855
[TBL] [Abstract][Full Text] [Related]
13. E-rosette formation in Graves' ophthalmopathy.
Sergott RC; Felberg NT; Savino PJ; Blizzard JJ; Schatz NJ
Invest Ophthalmol Vis Sci; 1979 Dec; 18(12):1245-51. PubMed ID: 92464
[TBL] [Abstract][Full Text] [Related]
14. [Muscle antigens recognized with autoantibodies in patients with Graves' ophthalmopathy].
Adler G
Endokrynol Pol; 1992; 43(1 Suppl):1-61. PubMed ID: 1345558
[TBL] [Abstract][Full Text] [Related]
15. Soluble intercellular adhesion molecule-1 (sICAM-1) concentrations in Graves' disease patients followed up for development of ophthalmopathy.
De Bellis A; Di Martino S; Fiordelisi F; Muccitelli VI; Sinisi AA; Abbate GF; Gargano D; Bellastella A; Bizzarro A
J Clin Endocrinol Metab; 1998 Apr; 83(4):1222-5. PubMed ID: 9543145
[TBL] [Abstract][Full Text] [Related]
16. Cellular and humoral autoimmune responses against human eye muscle membrane antigen in Graves' disease.
Molnár I; Németi K; Bokk A; Stenszky V; Balázs C; Farid NR
Acta Med Hung; 1990; 47(1-2):43-51. PubMed ID: 2280995
[TBL] [Abstract][Full Text] [Related]
17. Comparison of practical methods for urinary glycosaminoglycans and serum hyaluronan with clinical activity scores in patients with Graves' ophthalmopathy.
Martins JR; Furlanetto RP; Oliveira LM; Mendes A; Passerotti CC; Chiamolera MI; Rocha AJ; Manso PG; Nader HB; Dietrich CP; Maciel RM
Clin Endocrinol (Oxf); 2004 Jun; 60(6):726-33. PubMed ID: 15163337
[TBL] [Abstract][Full Text] [Related]
18. Measuring disease activity to predict therapeutic outcome in Graves' ophthalmopathy.
Terwee CB; Prummel MF; Gerding MN; Kahaly GJ; Dekker FW; Wiersinga WM
Clin Endocrinol (Oxf); 2005 Feb; 62(2):145-55. PubMed ID: 15670189
[TBL] [Abstract][Full Text] [Related]
19. Acetylcholine receptor antibodies in patients with Graves' ophthalmopathy.
Jacobson DM
J Neuroophthalmol; 1995 Sep; 15(3):166-70. PubMed ID: 8574362
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and significance of antibodies reactive with eye muscle membrane antigens in sera from patients with Graves' ophthalmopathy and other thyroid and nonthyroid diseases.
Wu YJ; Clarke EM; Shepherd P
Thyroid; 1998 Feb; 8(2):167-74. PubMed ID: 9510126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
